---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-005108"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:50:07.205957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics completes $7M IPO at $5/share and receives FDA Fast Track for tecarfarin

## Summary
- IPO of 1.4M shares at $5.00 closed Jan 24, raising $7.0M gross; stock trades on Nasdaq as CVKD.
- FDA granted Fast Track designation for tecarfarin in ESRD and atrial fibrillation patients.
- Appointed directors: Glynn Wilson (Class I), John Murphy (Class II), Steven Zelenkofske (Class III).
- Employment agreements: CFO Szot ($375K salary, 50% target bonus); CMO Losordo ($425K, 40% bonus).
- Issued 600K shares to HESP LLC, 1.14M on note conversion, 250K on warrant exercise.

## SEC filing metadata
- accession: 0001213900-23-005108
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-005108
- JSON: https://secwatch.observer/filing/0001213900-23-005108.json
- Plain text: https://secwatch.observer/filing/0001213900-23-005108.txt

## Key facts
- Executive change
  Douglas Losordo was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- Executive change
  Steven Zelenkofske was appointed as Class III Director at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: Steven Zelenkofske was appointed as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- Executive change
  John Murphy was appointed as Class II Director at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: John Murphy was appointed as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- Executive change
  Matthew Szot was appointed as Chief Financial Officer at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- Executive change
  Glynn Wilson was appointed as Class I Director at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: Glynn Wilson was appointed as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into Underwriting Agreement with Boustead Securities, LLC (as representative of the underwriters) valued at Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr (effective 2023-01-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Boustead Securities, LLC (as representative of the underwriters)
  - Value: Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr
  - Effective: 2023-01-19
  source text: On January 19, 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, as representative of the underwriters (the “Representative”), a form of which was previously filed as an exhibit to the Company’s registration statement on Form S-1, as amended (File No. 333-267562), which was declared effective by the Securities and Exchange Commission (the “Commission”) on January 19, 2023 (the “Registration Statement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.